دورية أكاديمية
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
| العنوان: | Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX |
|---|---|
| المساهمون: | Jonathan L Kaufman, Meletios A Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau, Heather J Sutherland, Hila Magen, Shinsuke Iida, Jin Seok Kim, H Miles Prince, Tara Cochrane, Albert Oriol, Nizar J Bahlis, Ajai Chari, Lisa O'Rourke, Sonali Trivedi, Tineke Casneuf, Maria Krevvata, Jon Ukropec, Rachel Kobos, Hervé Avet-Loiseau, Saad Z Usmani, Jesus San-Miguel, Kim, Jin Seok |
| بيانات النشر: | Nature Pub. Group |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Antibodies, Monoclonal / administration & dosage, Monoclonal / adverse effects, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Chromosome Deletion, Chromosomes, Human, Cytogenetic Analysis, Dexamethasone / administration & dosage, Dexamethasone / adverse effects, Disease-Free Survival, Humans, Lenalidomide / administration & dosage, Lenalidomide / adverse effects, Multiple Myeloma* / drug therapy, Multiple Myeloma* / genetics, Multiple Myeloma* / mortality, Recurrence, Survival Rate, Translocation, Genetic |
| الوصف: | High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10-5) was assessed via the clonoSEQ® assay V2.0. 569 patients were randomized (D-Rd, n = 286; Rd, n = 283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; P < 0.0001) and high cytogenetic risk (median: 26.8 vs 8.3 months; HR, 0.34; P = 0.0035) patients. Responses with D-Rd were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of cytogenetic risk. ; open |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2044-5385 |
| العلاقة: | BLOOD CANCER JOURNAL; J00342; OAK-2021-02634; https://ir.ymlib.yonsei.ac.kr/handle/22282913/183932Test; T202007248; BLOOD CANCER JOURNAL, Vol.10(11) : 111, 2020-11 |
| DOI: | 10.1038/s41408-020-00375-2 |
| الإتاحة: | https://doi.org/10.1038/s41408-020-00375-2Test https://ir.ymlib.yonsei.ac.kr/handle/22282913/183932Test |
| حقوق: | CC BY-NC-ND 2.0 KR |
| رقم الانضمام: | edsbas.10A2C067 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20445385 |
|---|---|
| DOI: | 10.1038/s41408-020-00375-2 |